Vertex builds in gene editing yet again, with $1.2bn Arbor dealVertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of Share XVertex builds in gene editing yet again, with $1.2bn Arbor dealhttps://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/
FDA rejects Provention’s type 1 diabetes drug teplizumabThe FDA indicated something was not well with Provention Bio’s filing for type 1 diabetes therapy teplizumab in Share XFDA rejects Provention’s type 1 diabetes drug teplizumabhttps://pharmaphorum.com/news/fda-rejects-proventions-type-1-diabetes-drug-teplizumab/
Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEONHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot Share XArtificial pancreas will be piloted in 1,000 diabetics, says NHS CEOhttps://pharmaphorum.com/news/artificial-pancreas-will-be-piloted-in-1000-diabetics-says-nhs-ceo/
Provention faces delay in FDA review of diabetes prevention antibodyThe FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for Share XProvention faces delay in FDA review of diabetes prevention antibodyhttps://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/
FDA fast tracks type 1 diabetes cell therapy from VertexVertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and Share XFDA fast tracks type 1 diabetes cell therapy from Vertexhttps://pharmaphorum.com/news/vertex-claims-fda-fast-track-status-for-diabetes-cell-therapy/
FDA approves Tandem’s connected insulin controllerTandem Diabetes Care has claimed approval in the US for a new software system that can be used Share XFDA approves Tandem’s connected insulin controllerhttps://pharmaphorum.com/news/fda-approves-tandems-connected-insulin-controller/
Sanofi builds case for Toujeo in younger type 1 diabeticsSanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but Share XSanofi builds case for Toujeo in younger type 1 diabeticshttps://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
Giving patients a sense of belongingClinical research professional and patient advocate Kristina Wolfe tells us how pharma can collaborate better with patients and Share XGiving patients a sense of belonginghttps://pharmaphorum.com/views-analysis-patients/giving-patients-a-sense-of-belonging/
